日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial

全球范围内启动 III 期临床试验的时间表:APHINITY 试验的子分析

Franzoi, Maria Alice; Procter, Marion; Twelves, Chris; Ponde, Noam; Eiger, Daniel; Emond, Orianne; Clark, Emma; Parlier, Damien; Guillaume, Sébastien; Reaby, Linda; de Azambuja, Evandro; Bines, Jose

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

APHINITY研究中患者报告的功能、健康相关生活质量和症状:帕妥珠单抗联合曲妥珠单抗和化疗治疗HER2阳性早期乳腺癌

Bines, José; Clark, Emma; Barton, Claire; Restuccia, Eleonora; Procter, Marion; Sonnenblick, Amir; Fumagalli, Debora; Parlier, Damien; Arahmani, Amal; Baselga, José; Viale, Giuseppe; Reaby, Linda L; Frank, Elizabeth; Gelber, Richard D; Piccart, Martine; Jackisch, Christian; Petersen, Jennifer A

Ascl1 as a novel player in the Ptf1a transcriptional network for GABAergic cell specification in the retina.

Ascl1 是 Ptf1a 转录网络中参与视网膜 GABA 能细胞分化的新型参与者

Mazurier Nicolas, Parain Karine, Parlier Damien, Pretto Silvia, Hamdache Johanna, Vernier Philippe, Locker Morgane, Bellefroid Eric, Perron Muriel